Truist raised the firm’s price target on Taysha Gene Therapies (TSHA) to $6 from $2 and keeps a Buy rating on the shares. The company’s Q2 data from the first adult Rett syndrome patient dosed with TSHA-102 is showing good tolerability and impressive efficacy, the analyst tells investors in a research note. The results also bode well for forthcoming pediatric data, which could trigger an opt-in by partner Astellas (ALPMY), the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies price target raised to $8 from $6 at Baird
- Why Taysha Gene Therapies (NASDAQ:TSHA) Doubled Its Value Today
- Cantor ups Taysha target to $7 from $2 after ‘robust’ Rett data
- Taysha Gene Therapies price target raised to $7 from $2 at Cantor Fitzgerald
- Taysha Gene Therapies expects cash to fund operations into 3Q25